Goldman Sachs Group Inc. increased its position in shares of Patheon NV (NASDAQ:PTHN) by 48.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,293 shares of the company’s stock after buying an additional 32,718 shares during the period. Goldman Sachs Group Inc. owned 0.07% of Patheon NV worth $2,642,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its position in Patheon NV by 0.8% in the first quarter. Bank of New York Mellon Corp now owns 90,080 shares of the company’s stock worth $2,373,000 after buying an additional 698 shares during the period. Alliancebernstein L.P. raised its stake in Patheon NV by 25.9% in the first quarter. Alliancebernstein L.P. now owns 13,027 shares of the company’s stock worth $343,000 after buying an additional 2,678 shares during the last quarter. Forward Management LLC raised its stake in Patheon NV by 67.4% in the first quarter. Forward Management LLC now owns 8,714 shares of the company’s stock worth $230,000 after buying an additional 3,509 shares during the last quarter. UBS Group AG raised its stake in Patheon NV by 57.9% in the first quarter. UBS Group AG now owns 11,072 shares of the company’s stock worth $291,000 after buying an additional 4,062 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Patheon NV during the first quarter worth approximately $185,000.
Shares of Patheon NV (NASDAQ:PTHN) traded down 0.03% during midday trading on Friday, hitting $34.96. The stock had a trading volume of 74,056 shares. The stock has a market cap of $5.07 billion and a PE ratio of 44.82. Patheon NV has a 52-week low of $23.72 and a 52-week high of $35.01. The firm has a 50 day moving average price of $34.90 and a 200-day moving average price of $31.16.
Patheon NV (NASDAQ:PTHN) last released its quarterly earnings data on Thursday, June 8th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. The company had revenue of $483.40 million for the quarter, compared to analysts’ expectations of $466.08 million. Patheon NV’s quarterly revenue was up 3.2% compared to the same quarter last year. Equities analysts predict that Patheon NV will post $1.14 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Goldman Sachs Group Inc. Acquires 32,718 Shares of Patheon NV (NASDAQ:PTHN)” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/08/11/goldman-sachs-group-inc-purchases-32718-shares-of-patheon-nv-nasdaqpthn-updated.html.
A number of analysts have commented on the company. Jefferies Group LLC reissued a “hold” rating and issued a $35.00 target price on shares of Patheon NV in a report on Friday, July 21st. Zacks Investment Research downgraded Patheon NV from a “buy” rating to a “hold” rating in a research note on Thursday, June 15th. Leerink Swann downgraded Patheon NV from an “outperform” rating to a “market perform” rating and raised their price target for the stock from $31.00 to $35.00 in a research note on Friday, June 9th. Raymond James Financial, Inc. downgraded Patheon NV from an “outperform” rating to a “mkt perform” rating in a research note on Friday, June 9th. Finally, J P Morgan Chase & Co downgraded Patheon NV from an “overweight” rating to a “neutral” rating in a research note on Thursday, June 8th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Patheon NV has an average rating of “Hold” and a consensus target price of $32.88.
Patheon NV Company Profile
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
What are top analysts saying about Patheon NV? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Patheon NV and related companies.